These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 33575430)
1. Automated generation of gene-edited CAR T cells at clinical scale. Alzubi J; Lock D; Rhiel M; Schmitz S; Wild S; Mussolino C; Hildenbeutel M; Brandes C; Rositzka J; Lennartz S; Haas SA; Chmielewski KO; Schaser T; Kaiser A; Cathomen T; Cornu TI Mol Ther Methods Clin Dev; 2021 Mar; 20():379-388. PubMed ID: 33575430 [TBL] [Abstract][Full Text] [Related]
2. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering. Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855 [TBL] [Abstract][Full Text] [Related]
3. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy. Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A Front Immunol; 2019; 10():2361. PubMed ID: 31649672 [TBL] [Abstract][Full Text] [Related]
4. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration. Malakhova E; Pershin D; Kulakovskaya E; Vedmedskaia V; Fadeeva M; Lodoeva O; Sozonova T; Muzalevskii Y; Kazachenok A; Belchikov V; Shelikhova L; Molostova O; Volkov D; Maschan M Cytotherapy; 2024 Jun; 26(6):567-578. PubMed ID: 38493403 [TBL] [Abstract][Full Text] [Related]
5. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells. Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809 [TBL] [Abstract][Full Text] [Related]
6. Automated, scaled, transposon-based production of CAR T cells. Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530 [TBL] [Abstract][Full Text] [Related]
7. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970 [TBL] [Abstract][Full Text] [Related]
8. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927 [TBL] [Abstract][Full Text] [Related]
9. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167 [TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related]
11. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611 [TBL] [Abstract][Full Text] [Related]
12. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD Glienke W; Dragon AC; Zimmermann K; Martyniszyn-Eiben A; Mertens M; Abken H; Rossig C; Altvater B; Aleksandrova K; Arseniev L; Kloth C; Stamopoulou A; Moritz T; Lode HN; Siebert N; Blasczyk R; Goudeva L; Schambach A; Köhl U; Eiz-Vesper B; Esser R Front Immunol; 2022; 13():839783. PubMed ID: 35401506 [TBL] [Abstract][Full Text] [Related]
13. Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform. Aleksandrova K; Leise J; Priesner C; Melk A; Kubaink F; Abken H; Hombach A; Aktas M; Essl M; Bürger I; Kaiser A; Rauser G; Jurk M; Goudeva L; Glienke W; Arseniev L; Esser R; Köhl U Transfus Med Hemother; 2019 Feb; 46(1):47-54. PubMed ID: 31244581 [TBL] [Abstract][Full Text] [Related]
15. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Nicod C; da Rocha MN; Warda W; Roussel X; Haderbache R; Seffar E; Trad R; Bouquet L; Goncalves M; Bosdure L; Laude MC; Guiot M; Ferrand C; Deschamps M Curr Res Transl Med; 2023; 71(2):103385. PubMed ID: 36773434 [TBL] [Abstract][Full Text] [Related]
16. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells. MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835 [TBL] [Abstract][Full Text] [Related]
17. Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. Joedicke JJ; Großkinsky U; Gerlach K; Künkele A; Höpken UE; Rehm A Mol Ther Methods Clin Dev; 2022 Mar; 24():181-198. PubMed ID: 35118163 [TBL] [Abstract][Full Text] [Related]
18. Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy. Gautron AS; Juillerat A; Guyot V; Filhol JM; Dessez E; Duclert A; Duchateau P; Poirot L Mol Ther Nucleic Acids; 2017 Dec; 9():312-321. PubMed ID: 29246309 [TBL] [Abstract][Full Text] [Related]
19. Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells. Hale M; Lee B; Honaker Y; Leung WH; Grier AE; Jacobs HM; Sommer K; Sahni J; Jackson SW; Scharenberg AM; Astrakhan A; Rawlings DJ Mol Ther Methods Clin Dev; 2017 Mar; 4():192-203. PubMed ID: 28345004 [TBL] [Abstract][Full Text] [Related]
20. Optimized two-step electroporation process to achieve efficient nonviral-mediated gene insertion into primary T cells. Yang M; Tkach D; Boyne A; Kazancioglu S; Duclert A; Poirot L; Duchateau P; Juillerat A FEBS Open Bio; 2022 Jan; 12(1):38-50. PubMed ID: 34510816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]